JP2022508167A - ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用 - Google Patents

ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用 Download PDF

Info

Publication number
JP2022508167A
JP2022508167A JP2021528866A JP2021528866A JP2022508167A JP 2022508167 A JP2022508167 A JP 2022508167A JP 2021528866 A JP2021528866 A JP 2021528866A JP 2021528866 A JP2021528866 A JP 2021528866A JP 2022508167 A JP2022508167 A JP 2022508167A
Authority
JP
Japan
Prior art keywords
compound
steroid
pharmaceutical composition
interferon gamma
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021528866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022508167A5 (enExample
Inventor
ヴラディミル エヴゲニエヴィチ ネボルシン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
'chemimmune Therapeutics' LLC
Original Assignee
'chemimmune Therapeutics' LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 'chemimmune Therapeutics' LLC filed Critical 'chemimmune Therapeutics' LLC
Publication of JP2022508167A publication Critical patent/JP2022508167A/ja
Priority to JP2022184210A priority Critical patent/JP7518997B2/ja
Publication of JP2022508167A5 publication Critical patent/JP2022508167A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021528866A 2018-11-23 2019-11-22 ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用 Pending JP2022508167A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022184210A JP7518997B2 (ja) 2018-11-23 2022-11-17 ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2018141291A RU2712281C1 (ru) 2018-11-23 2018-11-23 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
RU2018141291 2018-11-23
PCT/RU2019/050225 WO2020106191A1 (ru) 2018-11-23 2019-11-22 Производное глутаримида для преодоления резистентности к стероидам

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022184210A Division JP7518997B2 (ja) 2018-11-23 2022-11-17 ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用

Publications (2)

Publication Number Publication Date
JP2022508167A true JP2022508167A (ja) 2022-01-19
JP2022508167A5 JP2022508167A5 (enExample) 2023-01-25

Family

ID=69624712

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021528866A Pending JP2022508167A (ja) 2018-11-23 2019-11-22 ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用
JP2022184210A Active JP7518997B2 (ja) 2018-11-23 2022-11-17 ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022184210A Active JP7518997B2 (ja) 2018-11-23 2022-11-17 ステロイド耐性の克服および異常なインターフェロンガンマシグナル伝達に関連する疾患の治療のためのグルタルイミド誘導体の使用

Country Status (19)

Country Link
US (1) US20220362230A1 (enExample)
EP (2) EP4218758A3 (enExample)
JP (2) JP2022508167A (enExample)
KR (2) KR20220162821A (enExample)
CN (2) CN114652721A (enExample)
AU (2) AU2019384626A1 (enExample)
BR (1) BR112021009801A2 (enExample)
CA (1) CA3120882A1 (enExample)
CL (2) CL2021001316A1 (enExample)
EA (1) EA201992646A1 (enExample)
GE (4) GEAP202215712A (enExample)
IL (2) IL297533A (enExample)
MD (2) MD4844C1 (enExample)
MX (2) MX2021006032A (enExample)
MY (1) MY209416A (enExample)
PH (1) PH12021551152A1 (enExample)
RU (1) RU2712281C1 (enExample)
WO (1) WO2020106191A1 (enExample)
ZA (2) ZA202104247B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
WO2023191666A1 (ru) * 2022-03-29 2023-10-05 Общество С Ограниченной Ответственностью "Валента-Интеллект" Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07505617A (ja) * 1992-02-07 1995-06-22 クリグマン，アルバート　エム． 炎症性皮膚病の治療方法
JP2006521356A (ja) * 2003-03-28 2006-09-21 ファルマシア・コーポレーション シクロオキシゲナーゼ−２阻害薬を使用することによるステロイド節約効果をもたらす方法、およびシクロオキシゲナーゼ−２阻害薬を含む組成物
JP2016516766A (ja) * 2013-04-12 2016-06-09 オブシェストヴォ・ス・オグラニチェンノイ・オトヴェトストヴェンノストジュ・“ファームエンタープライジーズ” グルタルイミド誘導体、その使用、それに基づいた医薬組成物及びグルタルイミド誘導体を製造するための方法
JP2016540749A (ja) * 2013-11-14 2016-12-28 オブシェストヴォ・ス・オグラニチェンノイ・オトヴェトストヴェンノストジュ・“ファームエンタープライジーズ” グルタルイミド誘導体を含む医薬組成物、及び好酸球性疾患を処置するためのその適用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9111874U1 (de) * 1991-09-23 1991-11-21 Haag, Richard, 7181 Satteldorf Halterung zur Aufnahme und Befestigung von Akkus am Heckbrett in Booten
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US20090087425A1 (en) 2007-08-10 2009-04-02 Topigen Pharmaceuticals Inc. Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease
RU2404792C1 (ru) * 2009-05-20 2010-11-27 Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС" Средство для преодоления стероидной резистентности
US20140112913A1 (en) * 2011-02-10 2014-04-24 Genqual Corporation Methods of prognosing and administering treatment for inflammatory disorders
JP2014511181A (ja) 2011-02-24 2014-05-15 ファーマキシス リミテッド キメラ骨格および２−アミノ−２’−デオキシアデノシンを有するオリゴヌクレオチド阻害剤
GEP20227402B (en) * 2017-09-07 2022-08-10 Valenta Intellekt Ltd Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07505617A (ja) * 1992-02-07 1995-06-22 クリグマン，アルバート　エム． 炎症性皮膚病の治療方法
JP2006521356A (ja) * 2003-03-28 2006-09-21 ファルマシア・コーポレーション シクロオキシゲナーゼ−２阻害薬を使用することによるステロイド節約効果をもたらす方法、およびシクロオキシゲナーゼ−２阻害薬を含む組成物
JP2016516766A (ja) * 2013-04-12 2016-06-09 オブシェストヴォ・ス・オグラニチェンノイ・オトヴェトストヴェンノストジュ・“ファームエンタープライジーズ” グルタルイミド誘導体、その使用、それに基づいた医薬組成物及びグルタルイミド誘導体を製造するための方法
JP2016540749A (ja) * 2013-11-14 2016-12-28 オブシェストヴォ・ス・オグラニチェンノイ・オトヴェトストヴェンノストジュ・“ファームエンタープライジーズ” グルタルイミド誘導体を含む医薬組成物、及び好酸球性疾患を処置するためのその適用

Also Published As

Publication number Publication date
MD20210050A2 (ro) 2021-12-31
WO2020106191A1 (ru) 2020-05-28
EP4218758A2 (en) 2023-08-02
JP7518997B2 (ja) 2024-07-19
MD4851B1 (ro) 2023-04-30
PH12021551152A1 (en) 2021-10-25
GEP20237467B (en) 2023-02-10
MD4844C1 (ro) 2023-09-30
MD4844B1 (ro) 2023-02-28
AU2019384626A1 (en) 2021-07-15
CN114652721A (zh) 2022-06-24
IL283317A (en) 2021-07-29
ZA202210444B (en) 2023-01-25
MX2022013503A (es) 2022-11-16
EP4218758A3 (en) 2023-08-23
JP2023015333A (ja) 2023-01-31
EP3884945A1 (en) 2021-09-29
CA3120882A1 (en) 2020-05-28
IL297533A (en) 2022-12-01
AU2022256212A1 (en) 2022-12-08
MD4851C1 (ro) 2023-11-30
KR20220162821A (ko) 2022-12-08
CL2022000683A1 (es) 2022-10-28
RU2712281C1 (ru) 2020-01-28
CN113164464A (zh) 2021-07-23
CL2021001316A1 (es) 2021-10-29
GEP20247643B (en) 2024-07-10
EA201992646A1 (ru) 2020-05-31
MX2021006032A (es) 2021-07-06
KR20210095652A (ko) 2021-08-02
MY209416A (en) 2025-07-08
US20220362230A1 (en) 2022-11-17
AU2022256212B2 (en) 2024-08-15
GEAP202215712A (en) 2022-10-10
GEAP202415619A (en) 2024-03-11
ZA202104247B (en) 2023-03-29
BR112021009801A2 (pt) 2022-03-03
EP3884945A4 (en) 2022-11-23
MD20210032A2 (ro) 2021-09-30

Similar Documents

Publication Publication Date Title
Adcock et al. New targets for drug development in asthma
EP2533799B1 (en) Methods for the use of progestogen as a glucocorticoid sensitizer
US9078864B2 (en) Agonists for antimicrobial peptide systems
CN105228700A (zh) 左西替利嗪和孟鲁司特在治疗自身免疫病中的用途
CN108367012A (zh) 自体免疫性和自身炎症性疾病的治疗
AU2022256212B2 (en) Glutarimide derivative for overcoming resistance to steriods
US20140329782A1 (en) Combined therapeutic agent
US20210361674A1 (en) Treating Auto-Immune and Auto-Inflammatory Diseases
Yakar et al. The effect of tocilizumab on severe COVID-19 infection: Review of current evidence.
EA046267B1 (ru) Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
EA043839B1 (ru) Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
OA20833A (en) Use of Glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling.
OA20849A (en) Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling.
WO2004047866A2 (en) Use of the corticoliberin-urocortin system in the treatment of inflammatory diseases
JP7224303B2 (ja) 薬剤、組成物、及びそれに関連する方法
EP4703368A1 (en) Isolithocholic acid derivatives and use thereof
AU744734B2 (en) Mediation of cytokines by melanin
HK40059361A (en) Glutarimide derivative for overcoming resistance to steriods
WO2023143446A1 (en) Compositions and methods for treating cytokine storm
WO2023202439A1 (zh) 二萜化合物衍生物或其盐在制备防治特应性皮炎的药物中的应用
EP4702980A1 (en) Isolithocholic acid for use in the prevention or treatment of inflammatory diseases of the respiratory system
Wu et al. Novel Pathway for Intercepting Granular Exocytosis: A13 Engages APLNR to Drive FBXO28‐Mediated Ubiquitination and Proteasomal Clearance of Rab27a in Allergic Inflammation
KR20250173389A (ko) HIF-2α 저해제 및 스테로이드의 병용 투여용 조성물 및 이를 이용한 천식 예방, 개선 또는 치료방법
Fluticasone 21 CH2OH CH2OH CH2OH

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210521

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230113

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241119